Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00638794 · ClinicalTrials.gov registry record
Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents
A clinical trial of Coronary Artery Disease, sponsored by Cardiovascular Research Foundation, New York.
- Completed
- Registry status
- 8,575
- Enrollment target
- 8
- Study locations
NCT00638794: Completed study of Coronary Artery Disease, sponsored by Cardiovascular Research Foundation, New York.
NCT00638794 is a study of Coronary Artery Disease that has completed, run by Cardiovascular Research Foundation, New York. The registered enrollment target is 8,575 participants, above the 1,248-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (587% higher). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00638794, a study of Coronary Artery Disease, has completed, sponsored by Cardiovascular Research Foundation, New York.
- COMPLETED
- Registry status
- 8,575 participants
- Enrollment target
- 8
- Study locations
Study Summary
Prospective, multicenter, registry of at least 11,000 (and up to 15,000) consecutive patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications.
Conditions Studied
Interventions
- DEVICE Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)
Study Locations (8)
North Carolina
- Carolinas Medical Center - Charlotte
- LeBauer Cardiovascular Research - Greensboro
- FirstHealth Moore Regional Hospital - Pinehurst
Minnesota
- Minneapolis Heart Institute - Minneapolis
New York
- Columbia University Medical Center & New York Presbyterian - New York
Ohio
- Ohio State University Medical Center - Columbus
Pennsylvania
- Lehigh Valley Hospital and Health Network - Allentown
Tennessee
- Wellmont Holston Valley Medical Center - Kingsport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,575 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-01 |
What the finished NCT00638794 record still lists
NCT00638794 is an observational study that tracks outcomes without assigning an intervention. Its 8,575 participants enrollment target places it among the larger protocols in the corpus, above the 1,248-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (587% higher).
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™) is the first listed.
NCT00638794 lists 8 locations in 6 states (North Carolina, Minnesota, New York).
Frequently Asked Questions
What is clinical trial NCT00638794 about?
NCT00638794 is a clinical study titled "Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents". Prospective, multicenter, registry of at least 11,000 (and up to 15,000) consecutive patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications.
What is the current status of trial NCT00638794?
This trial is currently completed. The enrollment target is 8,575 participants. The study started on 2008-01. Estimated completion is 2013-01.
What conditions does trial NCT00638794 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT00638794?
The interventions under investigation include: Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™) (DEVICE).
Who is sponsoring clinical trial NCT00638794?
This trial is sponsored by Cardiovascular Research Foundation, New York, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00638794 being conducted?
This trial has 8 study locations across Minnesota, New York, North Carolina, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00638794's enrollment target sits among peer trials
8,575 7th of 219 higher than 213 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Factors Affect Outcomes in Cardiovascular Surgery
RECRUITING
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06098079 · 8,600 participants · Phase 4
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
- NCT06058234 · 8,680 participants
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
- NCT07185828 · 8,286 participants · NA
Informing Low-acuity Emergency Department Patients of Non-emergent Resources (2)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia